Cancer remains the second leading cause of death in the United States in 2026 — and the leading cause of death among Americans younger than 85. The American Cancer Society’s Cancer Statistics, 2026 report — published January 13, 2026 in CA: A Cancer Journal for Clinicians — projects that 2,114,850 Americans will be diagnosed with cancer in 2026 (approximately 5,800 new diagnoses every single day) and 626,140 will die from the disease — roughly 1,720 cancer deaths per day, or more than one death every minute. These numbers sit against a backdrop of genuinely extraordinary progress: the cancer mortality rate has declined 34% since its peak in 1991, and an estimated 4.8 million cancer deaths have been averted through 2023 as a direct result of smoking reduction, earlier detection, and improved treatment. Most strikingly, for the first time in history, the 5-year relative survival rate for all cancers combined has reached 70% for Americans diagnosed between 2015 and 2021 — up from 49% in the mid-1970s, representing a 21-percentage-point improvement that translates into millions of lives extended or saved.
The duality of the 2026 cancer data is striking: a sector achieving historic milestones in survival while simultaneously facing rising incidence across multiple cancer types. Lung cancer alone will cause more deaths in 2026 — approximately 125,000 — than the second-ranking (colorectal cancer) and third-ranking (pancreatic cancer) malignancies combined. Prostate cancer incidence continues to rise and is now diagnosed twice as often as second-ranking lung cancer among men. Breast, uterine, liver, melanoma, and oral cavity cancers are all trending upward in incidence. And the racial disparities that have always shadowed cancer statistics remain stubbornly persistent in 2026: Native American people have cancer mortality rates approximately twice those of White individuals for kidney, liver, stomach, and uterine cancers. Against this backdrop, proposed federal cuts to cancer research and health insurance threaten to halt progress precisely when the scientific momentum — immunotherapy, targeted therapy, personalised medicine — has never been stronger.
Interesting Facts: Cancer Death Rate Statistics 2026
CANCER IN THE US — 2026 SNAPSHOT (ACS Cancer Statistics 2026)
==============================================================
2026 Projections (American Cancer Society, January 13, 2026)
┌──────────────────────────────────────────────────────────┐
│ New diagnoses: 2,114,850 (~5,800 per day) │
│ Deaths: 626,140 (~1,720 per day) │
│ Deaths prevented since 1991: 4.8 million │
│ 5-year survival (all cancers, 2015–2021): 70% ██████ │
│ 5-year survival (mid-1970s): 49% ████ │
└──────────────────────────────────────────────────────────┘
Source: ACS Cancer Statistics, 2026 (CA: A Cancer Journal, Jan 2026)
Cancer's Rank as Cause of Death
┌──────────────────────────────────────────────────────────┐
│ #2 cause of death overall in the US │
│ #1 cause of death for Americans under age 85 │
└──────────────────────────────────────────────────────────┘
| Fact | Data (2026) |
|---|---|
| Projected new US cancer cases (2026) | 2,114,850 — approximately 5,800 per day |
| Projected US cancer deaths (2026) | 626,140 — approximately 1,720 per day |
| Cancer’s rank as US cause of death (overall) | #2 — second only to heart disease |
| Cancer’s rank for Americans under age 85 | #1 cause of death |
| Cancer mortality decline since 1991 peak | 34% overall reduction |
| Cancer deaths prevented since 1991 through 2023 | 4.8 million deaths averted |
| 5-year relative survival (all cancers combined, 2015–2021) | 70% — historic milestone; first time at this level |
| 5-year relative survival (mid-1970s baseline) | 49% — survival has risen 21 percentage points |
| 5-year survival: people living 5+ years since mid-1990s | Has doubled (Dr. William Dahut, ACS Chief Scientific Officer) |
| Daily cancer diagnoses in the US (2026) | ~5,800 people diagnosed every day |
| Total men diagnosed with cancer (2026) | 1,094,070 |
| Total women diagnosed with cancer (2026) | 1,020,780 |
| Lung cancer deaths (2026) | ~125,000 — more than #2 colorectal and #3 pancreatic combined |
| Deaths from smoking-related cancer (2026) | 182,830 — direct smoking or secondhand smoke exposure |
| US smoking prevalence: 1964 vs 2023 | 42% in 1964 → 11% in 2023 — key driver of mortality decline |
| Metastatic/distant-stage 5-year survival (2015–2021 vs mid-1990s) | 35% vs 17% — more than doubled |
| California: most new cancer diagnoses (2026) | ~206,500 projected — leading state |
| 4 cancers responsible for ~50% of all cancer deaths | Lung, colorectal, pancreatic, breast |
| Cancer research spending (US, threatened by federal cuts) | Proposed cuts flagged as threat to progress by ACS (January 2026) |
Source: American Cancer Society Cancer Statistics, 2026 (CA: A Cancer Journal for Clinicians, January 13, 2026), ACS Press Release (pressroom.cancer.org), ASCO Post (February 25, 2026), CancerNetwork (April 20, 2026), CURE Today (May 2026), SEER Cancer Stat Facts 2026, Fox News Health (January 16, 2026)
The 70% 5-year survival milestone is the defining headline of the 2026 cancer data, and it is genuinely historic. From 49% in the mid-1970s to 70% for those diagnosed between 2015 and 2021, this 21-percentage-point gain represents decades of investment in cancer biology research, clinical trials, imaging technology, surgical technique, radiation precision, chemotherapy regimens, and — most transformatively in the recent era — immunotherapy and targeted molecular therapy. “When we look at people who are surviving with cancer for at least five years, that number has doubled since the 1990s,” said Dr. William Dahut, Chief Scientific Officer of the American Cancer Society, at the January 2026 press conference. The doubling of long-term survival since the mid-1990s is not a marginal statistical gain; it is a transformed clinical reality for millions of patients who in a prior era would not have survived their diagnosis.
The 4.8 million deaths averted since 1991 is the cumulative ledger of that progress. This figure captures the gap between what the mortality rate would have been if it had stayed at its 1991 peak level and what it actually was in each subsequent year — a calculation that credits primarily to smoking reduction (which accounts for the largest share of lung cancer mortality decline), improved early detection through screening programmes (colonoscopy, mammography, PSA testing, low-dose CT for high-risk lung cancer), and treatment advances that have extended survival in diseases that were previously near-uniformly fatal. The challenge now is that incidence rates are rising in several cancer types simultaneously — pancreatic, prostate, breast, uterine, oral cavity — threatening to undo mortality progress through a sheer volume of new cases even if individual case-fatality rates continue to improve.
Cancer Death Rates by Type 2026 — US Data
TOP CANCER TYPES BY PROJECTED 2026 US DEATHS
=============================================
(ACS Cancer Statistics, 2026; SEER 2026)
Lung & Bronchus: ~125,000 ████████████████████████████████
Colorectal: ~57,600 ████████████████
Pancreatic: ~54,000 ███████████████
Breast (women): ~42,140 ████████████
Prostate: ~36,320 ██████████
Liver: ~30,000 █████████
Leukemia: ~24,000+ ███████
Non-Hodgkin Lymphoma:~20,000+ ██████
Lung + Colorectal + Pancreatic + Breast = ~50% of all cancer deaths
| Cancer Type | Projected 2026 Deaths (US) | 5-Year Survival Rate (2015–2021) | Trend |
|---|---|---|---|
| Lung & Bronchus | ~125,000 total (~64,190 men + ~60,540 women from 2025 data) | 28% — up from 15% in mid-1990s | Deaths declining; still #1 by far |
| Colorectal | ~57,600 (est.) | ~65% overall | Incidence rising in under-55; death rate falling in older adults |
| Pancreatic | ~54,000 (est.) | 13% — lowest of all major cancers | Rising incidence; very poor prognosis |
| Breast (women) | ~42,140 | ~91% (all stages) | Deaths declining 44% since 1989 |
| Prostate | ~36,320 | 98% (all stages) | Death rate down 53% since 1993 |
| Liver & Intrahepatic Bile Duct | ~30,000 (est.) | 22% — up from 7% in mid-1990s | Rising incidence and mortality |
| Leukemia | ~24,000+ | Varies widely by type | Improving for CML; poor for some AML |
| Non-Hodgkin Lymphoma | ~20,000+ | ~74% | Improving |
| Multiple Myeloma | Growing contributor | 62% — up from 32% | One of largest relative improvements |
| Melanoma (skin) | Notable contributor | 95% (all stages); metastatic 35% up from 16% | Strong improvement in metastatic |
| Uterine (corpus/endometrial) | ~13,780 (est.) | ~83% | Rising incidence; watch closely |
| Thyroid | Very low | 98% — highest of all cancers | Excellent prognosis |
| Esophageal | ~16,000+ | 22% | Persistently poor prognosis |
| Oral Cavity / Pharynx | Rising | Varies | Incidence rising for both genders |
Source: ACS Cancer Statistics, 2026 (CA: A Cancer Journal for Clinicians, January 13, 2026), SEER Cancer Stat Facts 2026, ASCO Post (February 25, 2026), CancerNetwork (April 20, 2026), OncLive (April 22, 2026), ACS Press Release (January 13, 2026)
The lung cancer data is simultaneously the greatest success story and the deepest ongoing tragedy in US cancer statistics. Success: lung cancer deaths have fallen 62% for men since 1990 and 38% for women since 2002 — the direct result of declining smoking rates, combined more recently with improved early detection via low-dose CT screening for high-risk individuals and the introduction of targeted therapies (EGFR inhibitors, ALK inhibitors) and immunotherapy (PD-1/PD-L1 checkpoint inhibitors) that have transformed outcomes for specific patient subgroups. Tragedy: despite these gains, lung cancer still kills approximately 125,000 Americans in 2026 — more than the #2 and #3 ranked cancers combined — because its base incidence was so enormous that even a 62% mortality reduction for men still leaves a colossal death toll. The fact that only 28% of all lung cancer patients survive 5 years (from 15% in the mid-1990s) reflects how late-stage most diagnoses remain and how limited treatment efficacy still is against the most common presentations.
Pancreatic cancer’s 13% 5-year survival rate places it in a uniquely grim category: virtually unchanged from historical rates, resistant to most therapeutic advances that have benefited other cancers, and diagnosed late in the majority of cases because early symptoms are vague and specific screening tests do not yet exist. Its rising incidence — flagged by the ACS as a concern for both genders in 2026 — means that even holding the survival rate constant will translate to more deaths in raw numbers as the incidence base grows. By contrast, multiple myeloma’s survival rate doubling from 32% to 62% since the mid-1990s represents one of the most dramatic improvement stories in modern oncology — driven by the sequential introduction of novel agents (thalidomide analogues, proteasome inhibitors, monoclonal antibodies, CAR-T therapies) that have transformed a uniformly fatal disease into a manageable chronic condition for many patients.
Cancer Survival Rates by Type — Record Highs 2026
5-YEAR RELATIVE SURVIVAL RATES — 2026
======================================
(ACS Cancer Statistics, 2026; diagnoses 2015–2021)
HIGHEST SURVIVAL:
Thyroid: 98% ████████████████████████████████████████
Prostate: 98% ████████████████████████████████████████
Testis: 95% ██████████████████████████████████████
Melanoma: 95% ██████████████████████████████████████
LOWEST SURVIVAL:
Pancreas: 13% █████
Liver: 22% █████████
Esophagus: 22% █████████
Lung: 28% ███████████
ALL CANCERS COMBINED:
Mid-1970s: 49% ████████████████████████████
2015–2021: 70% ████████████████████████████████████████
| Cancer Type | 5-Year Relative Survival (2015–2021) | Change from Mid-1990s | Notable |
|---|---|---|---|
| Thyroid | 98% — highest of all cancers | High historically | Excellent prognosis across stages |
| Prostate | 98% | Very high historically | Localised: near 100%; distant: 37% |
| Testis | 95% | High historically | Highly treatable at all stages |
| Melanoma (all stages) | 95% | Improved sharply — metastatic from 16% → 35% | Immunotherapy revolutionised outcomes |
| Breast (all stages) | ~91% | Strong improvement — deaths down 44% since 1989 | Localised: 99%; distant: ~31% |
| Non-Hodgkin Lymphoma | ~74% | Improved | Varies widely by subtype |
| Uterine (corpus) | ~83% | Moderate improvement | Rising incidence is concern |
| Colorectal | ~65% | Improved for older adults | Rising in under-55 cohort |
| Cervical | ~67% | Improved with HPV vaccine era beginning | HPV vaccination will reduce future rates |
| Leukemia (all types) | Varies (~65% aggregate) | Highly variable by subtype | CML: near-normal life expectancy with TKIs |
| Multiple Myeloma | 62% — up from 32% | One of largest absolute gains | CAR-T, novel agents driving gains |
| Liver | 22% — up from 7% | Tripled — still poor | Significant improvement from low base |
| Esophageal | 22% | Modest | Persistently poor prognosis |
| Lung (all stages) | 28% — up from 15% | Regional: 20% → 37%; Distant: 2% → 10% | Still lowest after pancreas and liver |
| Pancreatic | 13% — lowest of all major cancers | Minimal change | Urgent unmet clinical need |
| All cancers combined | 70% — historic milestone | Up from 49% (mid-1970s) | First time reaching 70% |
Source: ACS Cancer Statistics, 2026 (Siegel et al., CA: A Cancer Journal for Clinicians, January 13, 2026), SEER Cancer Stat Facts 2026, ASCO Post, CURE Today, OncLive, Fox News Health (January 2026)
The survival rate table is a ledger of both extraordinary human ingenuity and persistent biological resistance. The thyroid and prostate cancers at 98% 5-year survival represent diseases where the combination of early detection, indolent biology in many cases, and effective localised treatment protocols has essentially made long-term survival the expected outcome. The melanoma story is perhaps the most dramatic in the recent era: once a disease where a metastatic diagnosis carried only a 16% 5-year survival probability, the introduction of anti-PD-1 checkpoint inhibitors (pembrolizumab, nivolumab) and BRAF/MEK targeted therapy for BRAF-mutant disease has pushed metastatic melanoma survival to 35% — more than doubling the odds for patients with the most advanced presentations. This is not a marginal improvement; it is a categorical change in the meaning of a metastatic melanoma diagnosis.
The lung cancer regional-stage survival improvement from 20% to 37% and distant-stage from 2% to 10% captures a similar story at even larger scale. These gains are driven by immunotherapy — the introduction of pembrolizumab and nivolumab combinations that have converted what was uniformly a rapidly fatal disease into a condition where a meaningful subset of patients achieve durable multi-year responses. The fact that even with these gains, only 10% of patients with metastatic lung cancer survive 5 years shows how much further the field must travel. Pancreatic cancer at 13% remains the starkest symbol of where oncology has not yet made progress — essentially unchanged from historical rates, with late diagnosis, early metastasis, dense stromal barriers to drug delivery, and a uniquely immunosuppressive tumour microenvironment all contributing to a disease that has resisted virtually every treatment advance that has benefited other cancers.
Cancer Racial Disparities & Risk Factors 2026
CANCER RACIAL DISPARITIES — 2026 (ACS Cancer Statistics, 2026)
===============================================================
Cancer Mortality Rate Disparities vs White Americans:
┌──────────────────────────────────────────────────────────┐
│ Native American people: │
│ Kidney, liver, stomach, uterine cancers: ~2× higher │
│ Lung cancer mortality: HIGHEST nationally │
│ │
│ Black men: highest sex-specific cancer mortality │
│ Black patients: later-stage diagnoses, lower survival │
└──────────────────────────────────────────────────────────┘
Smoking-Attributable Cancer Deaths (2026):
┌──────────────────────────────────────────────────────────┐
│ 182,830 deaths linked to smoking / secondhand smoke │
│ Smoking causes 80%+ of lung and laryngeal cancers │
│ Smoking causes 50%+ of esophageal, oral, bladder cancers│
└──────────────────────────────────────────────────────────┘
| Racial Disparity / Risk Factor Metric | Data (2026) | Source |
|---|---|---|
| Native American people: cancer mortality vs White individuals | Death rates ~2× higher for kidney, liver, stomach, uterine cervix cancers | ACS Cancer Statistics, 2026 |
| Native American lung cancer mortality | Highest nationally — exceeds all other racial groups | ACS Cancer Statistics, 2026 |
| Black men: cancer mortality | Highest sex-specific cancer mortality rate of any demographic group | ACS Cancer Statistics, 2026 |
| Black patients: diagnosis stage | Later-stage diagnoses and lower survival — attributed to access, bias, trial underrepresentation | OncLive (April 2026) |
| Colorectal cancer Black/White disparity | ~Two-thirds of colorectal mortality disparity could be eliminated by equal-quality screening (OncLive) | OncLive (April 2026) |
| Prostate cancer: Black men | Incidence and mortality significantly higher than in White men | ACS 2026 |
| Cancer incidence: American Indian/Alaska Native | Highest incidence for multiple cancer types | ACS Cancer Statistics, 2026 |
| Smoking-attributable cancer deaths (2026) | 182,830 — direct use or secondhand exposure | CancerNetwork (April 2026) |
| Smoking prevalence: 1964 vs 2023 | 42% → 11% — decline credited as primary driver of mortality progress | ACS / OncLive (2026) |
| Lung + laryngeal cancers: smoking causation | Over 80% caused by smoking | ACS / CancerNetwork (2026) |
| Esophageal, oral/nasal, bladder cancers: smoking causation | ~50% caused by smoking | ACS / CancerNetwork (2026) |
| Lack of diversity in clinical trials | A key driver of disparities in treatment quality — “area of increasing focus” (ACS) | OncLive (April 2026) |
| Federal funding threat to cancer research (2026) | Proposed cuts flagged as threat to access to life-saving therapies and to halting research | CURE Today (May 2026); Fox News Health (Jan 2026) |
| California: highest projected cancer diagnoses by state | ~206,500 new cases projected in 2026 | OncLive / ACS Cancer Facts & Figures 2026 |
| Tobacco: leading cause of preventable death (US) | Despite smoking at 11%, tobacco remains the leading preventable cause of cancer death | ACS Cancer Statistics, 2026 |
Source: ACS Cancer Statistics, 2026 (January 13, 2026), ACS Cancer Facts & Figures 2026, ASCO Post (February 2026), OncLive (April 22, 2026), CancerNetwork (April 20, 2026), CURE Today (May 2026), Fox News Health (January 16, 2026)
The racial disparities in cancer mortality represent one of the most persistent failures in American oncology, and the 2026 data confirms that progress in average survival rates has not closed — and in some cases has widened — the gap between the best and worst served populations. Native American people facing cancer mortality rates twice those of White individuals for four major cancer types (kidney, liver, stomach, uterine) reflects geographic isolation from cancer screening programmes, underfunded Indian Health Service infrastructure, higher rates of risk factors including smoking and alcohol use, and systematic underrepresentation in the clinical trials that generated the evidence base for current standard-of-care treatments. The finding that Native American people have the highest lung cancer mortality of any racial group — exceeding even the already-elevated rates seen in high-smoking communities — places this community at the intersection of every risk and access disadvantage simultaneously.
The ACS’s observation that two-thirds of the Black/White colorectal cancer mortality disparity could be eliminated by ensuring equal quality of screening is a precise policy indictment: this is not a disparity driven primarily by biology or genetics, but by differential access to a preventive procedure that is highly effective when applied equitably. Black men’s position as the group with the highest sex-specific cancer mortality in the US — across multiple cancer types — reflects the compound effect of higher risk factor exposure, later-stage diagnosis due to lower screening rates and healthcare avoidance, and lower trial participation that limits the evidence base for optimised treatment in this population. The threat of federal cuts to cancer research and health insurance coverage flagged prominently by the ACS in January 2026 comes at precisely the moment when closing these disparities — through expanded Medicaid coverage, community-based screening, and diversified trial enrolment — would represent the single highest-yield investment available in US cancer control.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
